statement
파브리병 후보물질 HM15421의 기술이전 가치 1,404억원을 반영하고, 에피노페그듀타이드 가치를 2,788억원에서 5,133억원으로 상향했다.
A statement by 하나증권. Statements are as reported by the cited publishers — not verified by DecisionGateway.
파브리병 후보물질 HM15421 기술이전 가치 1,404억원 반영
Related claims
에피노페그듀타이드 2b상 결과는 11/5 AASLD 2026에서 공개됐다.하나증권 · statementHanAll Biopharma is forecast to post 2026 revenue of 169.3 billion KRW, operating profit of 12.0 billion KRW, and an operating margin of 7.1%.report author · predictionHanAll Biopharma is forecast to post 2027 revenue of 177.3 billion KRW, operating profit of 10.6 billion KRW, and an operating margin of 6.0%.report author · predictionFollowing the D2T RA clinical success, the risk discount is reduced from 50% to 40%, leading to a revaluation of IMVT-1402.report author · statement에피노페그듀타이드 10mg은 섬유화 개선 외 모든 항목에서 통계적 유의성을 충족했고, 보수적인 mITT 분석에서도 의미 있는 결과를 보였다.하나증권 · statement에이티넘인베스트먼트가 이노보테라퓨틱스에 150억을 투자해 7년 만에 결실을 봤다.kgrowth · statement
More claims by 하나증권
The report reviewed trends and major economic indicators in the U.S. and Chinese stock markets and analyzed valuations and trends by global sector.statementThe U.S. should watch AI-related regulation and volatility in the semiconductor sector, while for China domestic demand stimulus and policy effects will be key to a sustained rebound.statementThis report is a weekly report covering global sector trends and indicators rather than a single earnings estimate for an individual company, and it does not provide annual aggregate earnings figures.statementAn approach centered on core theme ETFs such as generative AI, semiconductors, quality and cybersecurity, and on major big tech stocks, remains valid.statementAhead of Nvidia's earnings release on 11/18, market attention is focused on Blackwell demand and next-generation GPU supply outlook.statement
All claims by 하나증권